Metagenomi focuses on developing new genome editing tools for genetic medicine. The company explores natural environments to discover and analyze genetic material, which is then sequenced and engineered into potential therapeutics. By utilizing artificial intelligence and high-throughput screening, Metagenomi can quickly identify efficient and specific genome editing tools from billions of novel proteins. This approach sets them apart from competitors who may not leverage such advanced technologies. The goal of Metagenomi is to create curative treatments for diseases through gene editing, aiming to significantly impact healthcare providers and patients in need.

Sozo Ventures

Bayer

Leaps by Bayer

RA Capital Management

InCube Ventures

Humboldt Fund

HOF Capital

Agent Capital

Novo Holdings

Pura Vida Investments

Bristol-Myers Squibb

Irving Investors

SymBiosis

Moderna Therapeutics

Eventide Asset Management

Frazier Healthcare Partners

Surveyor Capital

Marshall Wace

Farallon Capital Management

Deep Track Capital

PFM Health Sciences

Catalio Capital Management

Millennium Management

AI & Machine Learning

Biotechnology

Healthcare

Metagenomi

Metagenomi (Nasdaq: MGX), a precision genetic medicines company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.

Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference

METAGENOMI ALERT: Bragar Eagel & Squire, P.C. Reminds investors that a class action lawsuit has been filed against Metagenomi, Inc. and encourages investors to contact the firm.

METAGENOMI ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Metagenomi, Inc. and Encourages Investors to Contact the Firm

MGX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC announces that Metagenomi, Inc. investors with substantial losses have opportunity to lead Class Action lawsuit!

MGX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Glancy Prongay & Murray LLP reminds investors of looming deadline in the Class action lawsuit against Metagenomi, Inc. (MGX).

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Metagenomi, Inc. (MGX)

Investor notice: Robbins LLP informs stockholders of the class action lawsuit filed against Metagenomi Inc.

Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Metagenomi Inc.

Gainey McKenna & Egleston announces A class action lawsuit has been filed against Metagenomi Inc. (MGX).

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Metagenomi Inc. (MGX)

Under the October 2021 agreement, "Metagenomi was to utilize its gene editing systems in combination with Moderna's mRNA and LNP technologies" to develop new therapies for genetic diseases over a four-year span, Vreeland says.

Metagenomi Misrepresented Moderna Partnership, Investor Says (1)

Metagenomi Chief Scientific Officer Luis Borges has left the California-based biotech, according to a message posted on LinkedIn last week.Borges wrote that he has “parted ways with Metagenomi by mutual agreement,” noting that his time with the company “has been incredibly valuable.” Borges spent eight months with the biotech after being appointed in November 2023. He had previously been at Cell Medica and Century Therapeutics, serving as CSO for both companies.Metagenomi launched its bid to start trading on the Nasdaq Global Select Market during Borges’ tenure, initially aiming for an $86.9 million raise. Ultimately, the biotech put 6.25 million of its shares up for sale at $15 apiece for an initial public offering (IPO) of nearly $94 million.The market was not impressed, however, and Metagenomi’s stocks crashed nearly 31% on the day of its debut. The biotech has recently been trading at around $5.Metagenomi currently has no clinical-stage candidates, and its IPO highlights the difficulties preclinical biotechs may face should they seek to go public. The biotech is banking its business on what it calls “the most diverse genome editing toolbox,” which it envisions will be “capable of correcting any type of genetic mutation found anywhere in the genome.”Despite its relatively young pipeline, Metagenomi is backed by several high-profile supporters, including Bayer, which led its $275 million Series B fundraising round in January 2023. A few months earlier, in November 2022, Metagenomi entered into a gene editing partnership with Ionis, which could potentially lead to a $3 billion haul for the biotech.Borges’ departure comes months after Moderna backed out of its own gene editing contract with Metagenomi

Metagenomi Cso Steps Down Shortly After Ipo, Moderna Exit

Pictured: Entrance to Moderna's office in Massachusetts/iStock, hapabapaModerna has backed out of its gene editing deal with Metagenomi, handing back full global rights to the primary hyperoxaluria type 1 program and other related technologies, including base editors and RNA-mediated integration systems.Metagenomi in Wednesday’s announcement said that the partners have “mutually agreed” to terminate the agreement, but that the decision came after a “strategic prioritization” by Moderna. However, the mRNA-focused biopharma company will remain a shareholder of Metagenomi.Despite losing a powerhouse partner, Metagenomi CEO Brian Thomas said in a statement that the biotech is “pleased to regain full control of the development of base editing technology” and its RNA-mediated integration systems (RIGS), which will allow the company to harness these platforms to develop treatments in “areas of significant need, such as Alpha-1 antitrypsin deficiency and Wilson’s disease.”Metagenomi is capable of advancing programs on its own, Thomas said, adding that the biotech has over the years built up its footprint and talent base, as well as “leveraged significant private and public funding to greatly expand our gene editing toolbox, and established in-house manufacturing.”Moderna and Metagenomi inked the gene editing partnership in 2021, combining the former’s mRNA platform with the latter’s gene editing expertise to develop in vivo human therapies.At the time, the partners did not disclose the specific financial details of the deal, though subsequent SEC filings showed that Metagenomi could have potentially generated more than $3 billion from the agreement, plus an upfront payment and royalties. As of December 31, 2023, the biotech had secured $49.6 million from the partnership.In February 2024, Metagenomi debuted on the Nasdaq Global Select Market with a nearly $94 million initial public offering (IPO). The biotech’s shares cratered 31% the following day, highlighting the problems faced by earlier-stage companies that go public.Some of the market’s apprehension over Metagenomi’s IPO could be attributed to the fact that it has no candidates in the clinic. Instead, the biotech has focused on creating what it brands as “the most diverse genome editing toolbox” to target various genetic conditions.For Moderna, the discontinuation of the Metagenomi partnership comes after it suffered more than $1 billion in losses and write-downs linked to low demand for its vaccine and cancelled orders for Africa. The company has in turn suspended the construction of an mRNA manufacturing facility in Kenya while it assesses the demand for its vaccines.Tristan Manalac is an independent science writer based in Metro Manila, Philippines

Moderna Walks Away From Potential $3B Gene Editing Deal With Metagenomi

Metagenomi went public in February, raising nearly $94M through an initial public offering.

Jefferies, BMO bullish on newly public Metagenomi

Develops genome editing tools for therapeutics

Metagenomi

Develops genome editing tools for therapeutics

Metagenomi

Develops genome editing tools for therapeutics

About

Simplify's Take

What believers are saying

What critics are saying

What makes Metagenomi unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

Metagenomi is Hiring for 0 Jobs on Simplify!